A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.

doi:10.1016/j.dld.2013.10.002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Feb 2014

Francioso Simona, Almerighi Cristiana, Forte Paolo, Bandiera Franco, Nosotti Lorenzo, Lionetti Raffaella, Taliani Gloria, Piras Maria Rosaria, Ponti Maria Laura, Parruti Giustino, Di Candilo Francesco, Gentile Silvia, Piccolo Paola, Salso Angela, Riccobelli Francesca, Renzi Sara, Longo Maria Antonella, Montalbano Marzia, Zaru Salvatore, Biliotti Elisa, Di Masi Francesco, Santopaolo Francesco, Angelico Mario

Abstract excerpt

BACKGROUND: Rapid and early virological responses to peginterferon-alpha and ribavirin are predictive of sustained virological response (SVR) in hepatitis C virus (HCV) infection. We aimed at finding a simple rule to determine the shortest duration of dual therapy for all HCV genotypes, obtained by multiplying time to Initial Viral Response, IVR (first undetectable HCV-RNA) by 4 (Tailored Therapy-4, or TT4)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Precision Medicine

Share to Ribavirin

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 24239044
DOI: 10.1016/j.dld.2013.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.PMID 24239044Read ↗

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Optimal therapy of genotype-2 chronic hepatitis C: what's new?Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 4 patients.Semantic proximity Read ↗

Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.Semantic proximity Read ↗

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysisSemantic proximity Read ↗

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read ↗

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.Semantic proximity Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.